Targeting the Bromome: Are we there yet?

Future Medicinal Chemistry

Volumn 8, Issue 13, 2016, Pages 1529-1532

  Müller, Susanne ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

bromodomains; chemical probes; chromatin; epigenetics; open access; target validation

Indexed keywords

ABC TRANSPORTER; ACETIC ACID DERIVATIVE; ANTIINFECTIVE AGENT; ASPARAGINE; BROMODOMAIN INHIBITOR; CYTOPLASM PROTEIN; GAMMA INTERFERON; GLUTAMIC ACID; I CBP 112; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PHENYLALANINE; PROTEOME; THREONINE; TYROSINE; UNCLASSIFIED DRUG; E1A ASSOCIATED P300 PROTEIN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

CHROMATIN; DRUG TARGETING; ENHANCER REGION; GENE; GENE CONTROL; HISTONE CODE; HUMAN; NONHUMAN; PHYLOGENETIC TREE; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; EPIGENETICS; METABOLISM; PROTEIN DOMAIN;

CHROMATIN; E1A-ASSOCIATED P300 PROTEIN; EPIGENOMICS; HUMANS; NUCLEAR PROTEINS; PROTEIN DOMAINS; TRANSCRIPTION FACTORS;

EID: 84986300520     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc-2016-0136     Document Type: Review

References (23)

1. Brown PJ, Müller S. Open access chemical probes for epigenetic targets. Future Med. Chem. 7(14), 1901-1917 (2015
2. Flynn EM, Huang OW, Poy F, et al. A subset of human bromodomains recognizes butyryllysine and crotonyllysine histone peptide modifications. Structure 23(10), 1801-1814 (2015
3. Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149(1), 214-231 (2012
4. Picaud S, Fedorov O, Thanasopoulou A, et al. Generation of a selective small molecule inhibitor of the CBP/p300 bromodomain for leukemia therapy. Cancer Res. 75(23), 5106-5119 (2015
5. Conery AR, Centore RC, Neiss A, et al. Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. eLife 5, pii: e10483 (2016
6. Theodoulou NH, Tomkinson NC, Prinjha RK, Humphreys PG. Clinical progress and pharmacology of small molecule bromodomain inhibitors. Curr. Opin. Chem. Biol. 33, 58-66 (2016
7. Martin LJ, Koegl M, Bader G, et al. Structure-based design of an in vivo active selective BRD9 inhibitor. J. Med. Chem. 59(10), 4462-4475 (2016
8. Barbieri I, Cannizzaro E, Dawson MA. Bromodomains as therapeutic targets in cancer. Brief. Funct. Genomics 12(3), 219-230 (2013
9. Muller S, Filippakopoulos P, Knapp S. Bromodomains as therapeutic targets. Expert Rev. Mol. Med. 13, e29 (2011
10. Wu Q Sharma S, Cui H, et al. Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells. Oncotarget doi: 10.18632/oncotarget.8384 2016) (Epub ahead of print
11. Fedorov O, Castex J, Tallant C, et al. Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance. Sci. Adv. 1(10), e1500723 (2015
12. Gerstenberger BS, Trzupek JD, Tallant C, et al. Identification of a chemical probe for family VIII bromodomains through optimization of a fragment hit. J. Med. Chem. 59(10), 4800-4811 (2016
13. Winter GE, Buckley DL, Paulk J, et al. drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348(6241), 1376-1381 (2015
14. Theodoulou NH, Tomkinson NC, Prinjha RK, Humphreys PG. Progress in the development of non-bet bromodomain chemical probes. ChemMedChem 11(5), 477-487 (2016
15. SGC: Chemical Probes www.thesgc.org/chemical-probes
16. Sdelci S, Lardeau CH, Tallant C, et al. Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-Talk. Nat. Chem. Biol. 12(7), 504-510 (2016
17. Fairbridge NA, Dawe CE, Niri FH, Kooistra MK, King-Jones K, Mcdermid HE. Cecr2 mutations causing exencephaly trigger misregulation of mesenchymal/ectodermal transcription factors. Birth Defects Res. A Clin. Mol. Teratol. 88(8), 619-625 (2010
18. Sun H, Martin JA, Werner CT, et al. BAZ1B in nucleus accumbens regulates reward-related behaviors in response to distinct emotional stimuli. J. Neurosci. 36(14), 3954-3961 (2016
19. Yamada HY, Rao CV. BRD8 is a potential chemosensitizing target for spindle poisons in colorectal cancer therapy. Int. J. Oncol. 35(5), 1101-1109 (2009
20. Zhang X, Zhao D, Xiong X, He Z, Li H. Multifaceted histone H3 methylation and phosphorylation readout by the plant homeodomain finger of human nuclear antigen Sp100C. J. Biol. Chem. 291(24), 12786-12798 (2016
21. Harter MR, Liu CD, Shen CL, et al. BS69/ZMYND11 C-Terminal domains bind and inhibit EBNA2. PLoS Pathog. 12(2), e1005414 (2016
22. Philpott M, Rogers CM, Yapp C, et al. Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching. Epigenetics Chromatin 7, 14 (2014
23. Vidler LR, Brown N, Knapp S, Hoelder S. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J. Med. Chem. 55(17), 7346-7359 (2012